title: Postoperative vasopressin and copeptin levels in noncardiac surgery patients: a prospective controlled trial.
abstract: Further information on the endogenous arginine vasopressin (AVP) response in patients with postoperative systemic inflammatory response syndrome (SIRS) and vasodilatory shock would provide more insight into the pathophysiology of SIRS-associated cardiovascular failure and help indicate AVP therapy. Patients after uncomplicated abdominal surgery without SIRS (n = 10), critically ill patients after noncardiac surgery with SIRS (n = 9), and patients with SIRS plus vasodilatory shock (n = 22) were included in this prospective trial. Plasma AVP (radioimmunoassay) and copeptin (immunoluminometric assay) concentrations together with clinical parameters were documented daily during the first 7 days postoperative. The AVP response significantly differed between the three groups. Patients without SIRS had lower AVP concentrations than SIRS patients with (P = 0.001) or without shock (P = 0.003). Patients with SIRS and shock had higher AVP levels than patients with SIRS alone (P < 0.001). Arginine vasopressin decreased over time (P = 0.007) in all groups. At day 28, nonsurvivors had higher AVP levels than did survivors (P < 0.001). In SIRS patients without shock, serum osmolarity was indirectly associated with AVP levels, whereas mean arterial blood pressure and serum osmolarity were associated with AVP in SIRS patients with shock. Arginine vasopressin and copeptin correlated significantly with each other (P < 0.001; r = 0.76). In patients without hemofiltration, copeptin levels predicted 28-day mortality with high sensitivity and specificity. The postoperative AVP response in noncardiac surgery patients seems well maintained. The possibility that AVP plays a contributory role in the failure to restore vascular tone in patients with vasodilatory shock cannot be excluded but seems less important than in septic or postcardiotomy shock.
authors.affiliation: Departments of Anaesthesiology and Critical Care Medicine, Innsbruck Medical University, Innsbruck, Austria.
authors.forename: Stefan
authors.initials: S
authors.lastname: Jochberger
authors.forename: Matthias
authors.initials: M
authors.lastname: Zitt
authors.forename: Günter
authors.initials: G
authors.lastname: Luckner
authors.forename: Viktoria D
authors.initials: VD
authors.lastname: Mayr
authors.forename: Volker
authors.initials: V
authors.lastname: Wenzel
authors.forename: Hanno
authors.initials: H
authors.lastname: Ulmer
authors.forename: Nils G
authors.initials: NG
authors.lastname: Morgenthaler
authors.forename: Walter R
authors.initials: WR
authors.lastname: Hasibeder
authors.forename: Martin W
authors.initials: MW
authors.lastname: Dünser
mesh_terms: D000368:Aged; D001127:Arginine Vasopressin / Q000627:therapeutic use*; D005260:Female; D013502:General Surgery / Q000379:methods*; D006020:Glycopeptides / Q000378:metabolism*; D006440:Hemofiltration; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D018805:Sepsis / Q000628:therapy; D012984:Software; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D006020:Glycopeptides; C048197:copeptins; D001127:Arginine Vasopressin